[144] Janux Therapeutics, Inc. SEC Filing
Rhea-AI Filing Summary
Janux Therapeutics shareholder plans a sizable stock sale. A person identified as Andy Meyer has filed to sell 178,767 shares of JANX common stock through Morgan Stanley Smith Barney LLC on or around 01/26/2026 on the NASDAQ. The filing lists an aggregate market value of $2,601,113.48 for these shares, with 60,147,807 shares of common stock outstanding. The shares to be sold were acquired on 01/26/2026 by exercising options under a registered plan for cash. Over the prior three months, the same seller reported multiple JANX stock sales totaling several tranches, including 118,122 shares on 01/23/2026 and 16,665 shares on 10/28/2025.
Positive
- None.
Negative
- None.
Insights
Form 144 signals a planned, option-related JANX share sale.
The filing shows an individual shareholder in Janux Therapeutics planning to sell 178,767 shares of common stock, with an indicated aggregate market value of $2,601,113.48. These shares were acquired on 01/26/2026 via exercise of stock options under a registered plan, paid in cash, which is a typical mechanism for equity compensation realization.
The notice also lists prior sales over the last three months, including 118,122 shares sold on 01/23/2026 for gross proceeds of $1,738,389.66 and 16,665 shares sold on 10/28/2025 for $500,314.00. The filing ties the planned sale to Rule 144, which governs resales by affiliates and large holders and includes a representation that the seller is not aware of undisclosed material adverse information about the company’s operations.
Overall, this is a disclosure of a significant prospective share sale relative to a single holder, not a change in Janux’s underlying business. The impact on markets, if any, would depend on trading volume and investor perception once sales occur, while total shares outstanding are stated as 60,147,807.